证券代码：300391 证券简称：*ST 长药 公告编号：2025-099 长江医药控股股份有限公司 关于立案调查进展暨风险提示公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 重要风险提示： 1、公司存在重大违法强制退市风险。 3、公司存在财务类强制退市风险。 公司于2025年4月21日披露了《2024年年度报告》，经审计后的年度报告数 据显示，公司2024年度期末归属于上市公司股东的净资产为-432,840,659.21元。 根据《深圳证券交易所创业板股票上市规则》第10.3.1条第（二）项规定，上市 公司出现"最近一个会计年度经审计的期末净资产为负值"的情形，对其股票交 易实施退市风险警示。公司股票交易被实施退市风险警示后，根据《深圳证券交 易所创业板股票上市规则》第10.3.11条规定，上市公司因触及第10.3.1条第一 款情形，其股票交易被实施退市风险警示后，实际触及退市风险警示情形相应年 度次一年度出现以下情形之一的，深圳证券交易所决定终止其股票上市交易： 1）经审计的利润总额、净利润、扣除非经常性损益后的净利润三者孰低为 负值，且扣除后的营业收 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.21% on November 20, with Kanghui Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - *ST Changyao: Closed at 2.83, up 19.92% with a trading volume of 763,900 shares and a turnover of 197 million yuan [1] - Jinhua Co., Ltd.: Closed at 69.8, up 7.15% with a trading volume of 577,400 shares and a turnover of 505 million yuan [1] - Tailong Pharmaceutical: Closed at 7.44, up 3.33% with a trading volume of 344,200 shares and a turnover of 25.2 million yuan [1] - Conversely, Kanghui Co., Ltd. saw a decline of 3.72%, closing at 22.26 with a trading volume of 27,400 shares and a turnover of 61.69 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 143 million yuan from institutional investors, while retail investors saw a net inflow of 133 million yuan [2] - Key stocks with significant capital flow included: - Jinhua Co., Ltd.: Institutional net inflow of 99.64 million yuan, retail net outflow of 79.86 million yuan [3] - Zhongsheng Pharmaceutical: Institutional net inflow of 92.18 million yuan, retail net outflow of 51.91 million yuan [3] - Tailong Pharmaceutical: Institutional net inflow of 25.82 million yuan, retail net outflow of 31.90 million yuan [3]

Group 1 - Shanghai Xiba's stock price fell by 5.16% due to the announcement of investigations into short-term trading involving its employee director and vice president [1] - The China Securities Regulatory Commission (CSRC) issued investigation notices to multiple companies, indicating a broader crackdown on market misconduct [1][2] - The recent cases highlight typical violations in the capital market, including short-term trading, market manipulation, and financial fraud [3] Group 2 - Regulatory measures are intensifying, with increased penalties for violations, such as raising the maximum fine for financial fraud from 600,000 to 10 million yuan [4] - The judicial system is reflecting these changes, as seen in the sentencing of Meng Qingshan from Meihua Biological, which exemplifies the new legal landscape [4] - Strengthened regulation and higher costs for violations are expected to reshape the A-share market environment, reducing the incentive for market participants to engage in misconduct [4]

Core Viewpoint - The current A-share market is characterized by a paradox where retail investors are experiencing significant losses while institutional investors are increasing their positions, indicating a potential market bottom and the possibility of a forthcoming bull market [1][3]. Market Behavior - In November 2025, the market fluctuated between 3300 and 3400 points, with trading volumes varying from over 1 trillion to below 800 billion [1]. - The current market resembles the pre-bull market phases of 2014 and early 2019, marked by sideways trading and widespread declines in individual stocks [1]. Institutional vs Retail Dynamics - As 90% of retail investors face losses, institutional funds are quietly accumulating shares, with data showing that institutional buying exceeded 300 million in certain stocks during declines, while retail holdings dropped by approximately 40% [3]. - The phenomenon of "panic selling" aligns with typical characteristics of a mid-bull market consolidation phase [3]. Broker Performance - Historically, broker stocks have been pivotal in initiating bull markets, but in November 2025, the broker sector is underperforming, which may indicate a buildup of energy before a potential breakout [4]. - The concentration of retail holdings in the broker sector has decreased to levels similar to those seen in 2020 [4]. Capital Flows - There is a significant shift in capital, with non-bank deposits increasing by 2.1 trillion in July 2025, indicating a trend of funds moving from savings to the stock market [6]. - Foreign capital is also returning, with sovereign funds from countries like Saudi Arabia increasing their A-share holdings by over 10 billion [6]. Timing and Market Signals - Historically, bull markets have often started in late November, with previous instances in 2014 and 2020 leading to substantial index gains [7]. - Current market conditions, including a supportive policy environment and technical indicators, suggest a potential rapid rise in the index if the securities and technology sectors conclude their consolidation [7]. Sectoral Disparities - The market is experiencing significant sectoral divergence, with certain sectors like AI and humanoid robots seeing gains over 200% since May 2025, while traditional sectors like banking and real estate remain sluggish [9]. - Institutional investors are strategically focusing on high-barrier technology sectors, such as solid-state batteries, rather than the entire industry chain [10].

Core Points - *ST Changyao has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false financial reporting [1] - Investors who purchased shares between March 30, 2019, and April 29, 2024, may have the opportunity to claim compensation if they sold or still hold shares at a loss after April 30, 2024 [1] Summary by Sections Company Investigation - The CSRC has decided to initiate a case against *ST Changyao due to allegations of false records in periodic financial reports [1] Investor Compensation - According to lawyer Xu Jin, investors can file civil compensation lawsuits without prior procedures due to new judicial interpretations regarding securities false statements [1] - Compensation claims may include losses from investment differences, stamp duty, and commission losses [1] Claim Conditions - Investors must have bought shares between March 30, 2019, and April 29, 2024, and must have sold or still hold shares at a loss after April 30, 2024, to qualify for claims [1] - Required materials for claims include a copy of the ID, confirmation of securities account opening, and transaction records stamped by the brokerage [1]

Market Overview - During the week of November 10 to November 14, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index closing at 3990.49 points, down 0.18% for the week, the Shenzhen Component Index at 13216.03 points, down 1.40%, and the ChiNext Index at 3111.51 points, down 3.01% [2] - Over 56% of individual stocks experienced gains during the week, with 170 stocks rising over 15% and 23 stocks declining over 15%. Sectors such as textiles, retail, beauty care, biomedicine, and food and beverage saw increases, while communication, electronics, computers, machinery, and defense industries faced declines [2] Top Performing Stocks - Huasheng Lithium Battery (688353.SH) led the weekly gainers with a remarkable 79.61% increase, followed by Haike Xinyuan (301292.SZ) at 71.38%. Other notable gainers included Jindike (688670.SH), Furui Shares (002083.SZ), Renmin Tongtai (600829.SH), and Dongbai Group (600693.SH), all exceeding 61% in weekly gains [4] - The stock price of Huasheng Lithium Battery reached a historical high, closing at 139.20 yuan, with a total market capitalization of 22.2 billion yuan. The stock has seen a cumulative increase of over 172% from November 5 to November 14 [5][6] Huasheng Lithium Battery Details - Huasheng Lithium Battery specializes in the research, production, and sales of lithium battery electrolyte additives, with a significant market presence in China and exports to Japan, South Korea, the United States, Europe, and Southeast Asia. The company ranked first in domestic market share for lithium-ion battery electrolyte additives from 2018 to 2020 [5] - The recent price surge in the electrolyte industry has driven the prices of additive products higher, with battery-grade vinyl carbonate rising from 48,800 yuan/ton to 57,000 yuan/ton in October, and a significant daily increase of 8.13% to 66,500 yuan/ton on November 10 [5][6] Underperforming Stocks - *ST Changyao (300391.SZ) was the worst performer of the week, with a decline of 33.62%. Other stocks such as Haitan Shares (603759.SH), Degute (300950.SZ), and Bangji Technology (603151.SH) also saw declines exceeding 17% [9] - The company is under investigation by the China Securities Regulatory Commission for suspected financial fraud, which may lead to forced delisting if significant violations are confirmed [10][11] *ST Changyao Company Overview - *ST Changyao operates in the pharmaceutical industry, focusing on the production and sales of traditional Chinese medicine pieces, medicinal capsules, and medical logistics. The company has faced challenges, including a warning of potential delisting due to negative net profits over the past three years [10][11] - The company reported a revenue of 105 million yuan for the first three quarters of 2025, a year-on-year increase of 4.4%, but a net loss of 210 million yuan, a decline of 15.89% [12]

Core Viewpoint - *ST Changyao is embroiled in a financial fraud scandal, facing a formal investigation by the China Securities Regulatory Commission (CSRC) due to suspected false reporting of financial data, which could lead to mandatory delisting if deemed a major violation [1][2]. Group 1: Financial Fraud Investigation - The investigation focuses on the authenticity of *ST Changyao's financial data, highlighting severe deficiencies in its information disclosure quality and internal control systems [2]. - The company has already been warned of delisting risks due to a negative net asset value reported for the fiscal year 2024 [2]. Group 2: Deteriorating Operations - Since entering the pharmaceutical industry in 2020 and fully transforming in 2022, *ST Changyao has not achieved expected growth, with revenue plummeting from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [3]. - The company's net profit has been negative for consecutive years, with net assets reported at -433 million yuan by the end of 2024, worsening to -643 million yuan by the end of Q3 2025 [3]. - Operating cash flow has been negative for three consecutive years, raising significant doubts about the company's ability to continue as a going concern [3]. Group 3: Legal and Financial Risks - *ST Changyao is facing multiple legal challenges, with 140 lawsuits involving a total amount of 1.878 billion yuan, which is 434% of its net assets, indicating governance issues and compliance failures [4]. - The company has 1.106 billion yuan in interest-bearing liabilities, with 390 million yuan overdue, leading to severe liquidity issues [4]. - A significant portion of the company's bank accounts, 67.7%, are frozen, impacting daily operations and cash flow management [4]. Group 4: Conclusion - *ST Changyao is undergoing its most severe test since its listing, facing a crisis that requires urgent resolution of debts and regulatory concerns to maintain its position in the capital market [5].

New Stock Issuance - Cash option declaration period for Hangzhou Steam Turbine (200771) is from November 19 to November 25, 2025[1] - Acquisition request period for Hailianxun (300277) is from November 12 to November 18, 2025[1] Trading Alerts - Severe abnormal fluctuation reported for Haike Xinyuan (301292) on November 11, 2025[1] - Abnormal fluctuation noted for ST Yuancheng (603388) on November 11, 2025[1] Company Announcements - Announcement for Tianji Co., Ltd. (002759) on November 13, 2025[1] - Announcement for Huatong Technology (688109) on November 13, 2025[1] Other Notable Events - ST Meigu (000615) reported on November 13, 2025[1] - ST Zhongdi (000609) reported on November 13, 2025[1]

New Stock Issuance - The stock code 300277 (Hai Lian Xun) has a subscription period for acquisition rights from November 12 to November 18, 2025[1] - Stock code 688353 (Hua Sheng Lithium) reported severe abnormal fluctuations on November 11, 2025[1] - Stock code 603122 (He Fu China) has an announcement dated November 8, 2025[1] Trading Alerts - Stock code 601888 (China Zhong Mian) has an announcement dated November 12, 2025[1] - Stock code 600537 (Yi Jing Guang Dian) has an announcement dated November 12, 2025[1] - Stock code 688028 (Wo Er De) has an announcement dated November 12, 2025[1] Abnormal Fluctuations - Stock code 600815 (Xia Gong Co.) reported abnormal fluctuations on November 6, 2025[2] - Stock code 603557 (ST Qi Bu) reported abnormal fluctuations on November 7, 2025[3] - Stock code 002478 (Chang Bao Co.) reported abnormal fluctuations on November 7, 2025[3]

证券代码：300391 证券简称：*ST 长药 公告编号：2025-098 长江医药控股股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、股票交易异常波动情况 5、经问询，本次股票异常波动期间，公司控股股东、实际控制人未发生买 卖公司股票的行为。 6、公司不存在需披露业绩预告的情况。 7、目前公司日常经营管理工作没有显著变化。 三、不存在应披露而未披露信息的说明 长江医药控股股份有限公司（以下简称"公司"）股票于2025年11月10日、 2025年11月11日连续2个交易日内日收盘价格跌幅偏离值累计-34.98%，根据《深 圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情形。敬请广大 投资者注意投资风险。 二、公司关注并核实情况说明 针对本次公司股票交易异常波动，公司董事会就相关事项进行了核实与自查， 具体情况如下： 1、公司前期披露的信息目前不存在需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、2025年11月7日，公司收到中国证券监督管理委 ...